clofazimine has been researched along with sq 109 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biava, M; Cocozza, M; Consalvi, S; Poce, G | 1 |
| Ekins, S; Kyaw Zin, PP; Makarov, V; Reynolds, RC; Salina, E | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Castagnolo, D; Denny, WA; Dos Santos, JL; Fernandes, GFS; Thompson, AM | 1 |
| Clemens, DL; Dillon, BJ; Ho, CM; Horwitz, MA; Lee, BY; Masleša-Galić, S; Nava, S; Silva, A | 1 |
4 review(s) available for clofazimine and sq 109
| Article | Year |
|---|---|
SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Molecule Property Analyses of Active Compounds for
Topics: Antitubercular Agents; Bacterial Proteins; Drug Discovery; Drug Resistance, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Nucleoside-Phosphate Kinase; Structure-Activity Relationship; Tuberculosis | 2020 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Tuberculosis Drug Discovery: Challenges and New Horizons.
Topics: Antitubercular Agents; COVID-19 Drug Treatment; Drug Discovery; Humans; Mycobacterium tuberculosis; Tuberculosis | 2022 |
1 other study(ies) available for clofazimine and sq 109
| Article | Year |
|---|---|
Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility.
Topics: Adamantane; Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Combinations; Ethylenediamines; Humans; Lung; Mice; Mycobacterium tuberculosis; Pyrazinamide; Tuberculosis | 2018 |